[1] Liga R, Neglia D.  Emerging F-18-labelled PET myocardial perfusion tracers[J]. Curr Cardiol Rep, 2020, 22(10): 116-.   doi: 10.1007/s11886-020-01368-0
[2]

Takafuji M, Kitagawa K, Ishida M, et al. Clinical validation of the accuracy of absolute myocardial blood flow quantification with dual-source CT using 15O-water PET[J/OL]. Radiol Cardiothorac Imaging, 2021, 3(5): e210060[2021-12-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581586. DOI: 10.1148/ryct.2021210060.
[3] Maaniitty T, Stenström I, Saraste A, et al.  Extensive and balanced reduction of myocardial blood flow in patients with suspected obstructive coronary artery disease: 15O-water PET study[J]. Int J Cardiol, 2021, 338: 1-7.   doi: 10.1016/j.ijcard.2021.06.012
[4] Maddahi J, Packard RRS.  Cardiac PET perfusion tracers: current status and future directions[J]. Semin Nucl Med, 2014, 44(5): 333-343.   doi: 10.1053/j.semnuclmed.2014.06.011
[5] Werner RA, Chen XY, Rowe SP, et al.  Moving into the next era of PET myocardial perfusion imaging: introduction of novel 18F-labeled tracers[J]. Int J Cardiovasc Imaging, 2019, 35(3): 569-577.   doi: 10.1007/s10554-018-1469-z
[6] Nekolla SG, Reder S, Saraste A, et al.  Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model[J]. Circulation, 2009, 119(17): 2333-2342.   doi: 10.1161/CIRCULATIONAHA.108.797761
[7]

Wang J, Mpharm SL, Liu TW, et al. Preliminary and comparative experiment study between 18F-Flurpiridaz and 13N-NH3·H2O myocardial perfusion imaging with PET/CT in miniature pigs[J]. Mol Imaging, 2020, 19: 1536012120947506. DOI: 10.1177/1536012120947506.
[8] Maddahi J, Czernin J, Lazewatsky J, et al.  Phase Ⅰ, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest[J]. J Nucl Med, 2011, 52(9): 1490-1498.   doi: 10.2967/jnumed.111.092528
[9] Berman DS, Maddahi J, Tamarappoo BK, et al.  Phase Ⅱ safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography[J]. J Am Coll Cardiol, 2013, 61(4): 469-477.   doi: 10.1016/j.jacc.2012.11.022
[10] Maddahi J, Lazewatsky J, Udelson JE, et al.  Phase-Ⅲ clinical trial of fluorine-18 flurpiridaz positron emission tomography for evaluation of coronary artery disease[J]. J Am Coll Cardiol, 2020, 76(4): 391-401.   doi: 10.1016/j.jacc.2020.05.063
[11] Feher A, Sinusas AJ.  Quantitative assessment of coronary microvascular function: dynamic single-photon emission computed tomography, positron emission tomography, ultrasound, computed tomography, and magnetic resonance imaging[J]. Circ Cardiovasc Imaging, 2017, 10(8): e006427-.   doi: 10.1161/CIRCIMAGING.117.006427
[12] 李剑明, 杨敏福, 何作祥.  放射性核素心肌血流定量显像在冠状动脉微血管功能障碍中的应用价值[J]. 中华心血管病杂志, 2020, 48(12): 1073-1077.   doi: 10.3760/cma.j.cn112148-20200426-00349
Li JM, Yang MF, He ZX.  Application value of radionuclide myocardial blood flow quantitative imaging in evaluating coronary microvascular dysfunction[J]. Chin J Cardiol, 2020, 48(12): 1073-1077.   doi: 10.3760/cma.j.cn112148-20200426-00349
[13] 彭琨, 陈卫强, 李剑明.  冠状动脉血流储备分数、心肌血流储备和微循环阻力指数在冠心病患者中的临床应用价值[J]. 国际放射医学核医学杂志, 2019, 43(5): 462-467.   doi: 10.3760/cma.j.issn.1673-4114.2019.05.014
Peng K, Chen WQ, Li JM.  Clinical application values of coronary flow reserve, myocardial flow reserve and index of microcirculatory resistance for patients with coronary artery diseases[J]. Int J Radiat Med Nucl Med, 2019, 43(5): 462-467.   doi: 10.3760/cma.j.issn.1673-4114.2019.05.014
[14] Shiraishi S, Tsuda N, Sakamoto F, et al.  Clinical usefulness of quantification of myocardial blood flow and flow reserve using CZT-SPECT for detecting coronary artery disease in patients with normal stress perfusion imaging[J]. J Cardiol, 2020, 75(4): 1-10.   doi: 10.1016/j.jjcc.2019.09.006
[15] Klein R, Beanlands RSB, deKemp RA.  Quantification of myocardial blood flow and flow reserve: technical aspects[J]. J Nucl Cardiol, 2010, 17(4): 555-570.   doi: 10.1007/s12350-010-9256-9
[16] Taqueti VR, Hachamovitch R, Murthy VL, et al.  Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization[J]. Circulation, 2015, 131(1): 19-27.   doi: 10.1161/CIRCULATIONAHA.114.011939
[17] Moody JB, Poitrasson-Rivière A, Hagio T, et al.  Added value of myocardial blood flow using 18F-flurpiridaz PET to diagnose coronary artery disease: the flurpiridaz 301 trial[J]. J Nucl Cardiol, 2021, 28(5): 2313-2329.   doi: 10.1007/s12350-020-02034-2
[18] Neglia D, Sampietro T, Vecoli C, et al.  Abnormal glucose and lipid control in non-ischemic left ventricular dysfunction[J]. J Nucl Cardiol, 2012, 19(6): 1182-1189.   doi: 10.1007/s12350-012-9609-7
[19] Ziadi MC, Dekemp RA, Williams KA, et al.  Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia[J]. J Am Coll Cardiol, 2011, 58(7): 740-748.   doi: 10.1016/j.jacc.2011.01.065
[20] Murthy VL, Naya M, Foster CR, et al.  Improved cardiac risk assessment with noninvasive measures of coronary flow reserve[J]. Circulation, 2011, 124(20): 2215-2224.   doi: 10.1161/CIRCULATIONAHA.111.050427
[21] Schindler TH, Schelbert HR, Quercioli A, et al.  Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health[J]. JACC Cardiovasc Imaging, 2010, 3(6): 623-640.   doi: 10.1016/j.jcmg.2010.04.007
[22] 彭琨, 陈卫强, 王永德, 等.  13N-NH3·H2O PET/CT显像血流储备测定对冠状动脉微血管疾病的诊断价值[J]. 中华核医学与分子影像杂志, 2019, 39(12): 708-713.   doi: 10.3760/cma.j.issn.2095-2848.2019.12.002
Peng K, Chen WQ, Wang YD, et al.  Diagnostic value of blood flow reserve measurement with 13N-NH3·H2O PET/CT imaging in patients with coronary microvascular disease[J]. Chin J Nucl Med Mol Imaging, 2019, 39(12): 708-713.   doi: 10.3760/cma.j.issn.2095-2848.2019.12.002
[23] Bourque JM, Hanson CA, Agostini D, et al.  Assessing myocardial perfusion in suspected coronary artery disease: rationale and design of the second phase 3, open-label multi-center study of flurpiridaz (F-18) injection for positron emission tomography (PET) imaging[J]. J Nucl Cardiol, 2021, 28(3): 1105-1116.   doi: 10.1007/s12350-021-02527-8
[24] Guehl NJ, Normandin MD, Wooten DW, et al.  Single-scan rest/stress imaging: validation in a porcine model with 18F-flurpiridaz[J]. Eur J Nucl Med Mol Imaging, 2017, 44(9): 1538-1546.   doi: 10.1007/s00259-017-3684-6
[25] Packard RRS, Huang SC, Dahlbom M, et al.  Absolute quantitation of myocardial blood flow in human subjects with or without myocardial ischemia using dynamic flurpiridaz F 18 PET[J]. J Nucl Med, 2014, 55(9): 1438-1444.   doi: 10.2967/jnumed.114.141093
[26] Danad I, Raijmakers PG, Appelman YE, et al.  Coronary risk factors and myocardial blood flow in patients evaluated for coronary artery disease: a quantitative [15O]H2O PET/CT study[J]. Eur J Nucl Med Mol Imaging, 2012, 39(1): 102-112.   doi: 10.1007/s00259-011-1956-0
[27] Duvernoy CS, Meyer C, Seifert-Klauss V, et al.  Gender differences in myocardial blood flow dynamics: lipid profile and hemodynamic effects[J]. J Am Coll Cardiol, 1999, 33(2): 463-470.   doi: 10.1016/s0735-1097(98)00575-0
[28] Taqueti VR, Shaw LJ, Cook NR, et al.  Excess cardiovascular risk in women relative to men referred for coronary angiography is associated with severely impaired coronary flow reserve, not obstructive disease[J]. Circulation, 2017, 135(6): 566-577.   doi: 10.1161/CIRCULATIONAHA.116.023266
[29]

Schelbert HR. Positron emission tomography of the heart: methodology, findings in the normal and the diseased heart, and clinical applications[M]//Phelps ME. PET: molecular imaging and its biological applications. New York: Springer, 2004: 389−508. DOI: 10.1007/978-0-387-22529-6_6.
[30] Knaapen P.  Quantitative myocardial blood flow imaging: not all flow is equal[J]. Eur J Nucl Med Mol Imaging, 2014, 41(1): 116-118.   doi: 10.1007/s00259-013-2585-6
[31] Murthy VL, Bateman TM, Beanlands RS, et al.  Clinical quantification of myocardial blood flow using PET: joint position paper of the SNMMI cardiovascular council and the ASNC[J]. J Nucl Med, 2018, 59(2): 273-293.   doi: 10.2967/jnumed.117.201368